DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
USA - NYSE:DOCS - US26622P1075 - Common Stock
68.05 USD
+1.02 (+1.52%)
68.05 USD
0 (0%)
DOCS gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 35 industry peers in the Health Care Technology industry. DOCS gets an excellent profitability rating and is at the same time showing great financial health properties. DOCS is valued quite expensive, but it does show an excellent growth. With these ratings, DOCS could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year DOCS was profitable.
In the past year DOCS had a positive cash flow from operations.
In the past 5 years DOCS has always been profitable.
Each year in the past 5 years DOCS had a positive operating cash flow.
1.2 Ratios
DOCS has a better Return On Assets (19.52%) than 100.00% of its industry peers.
With an excellent Return On Equity value of 22.93%, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 18.77%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for DOCS is significantly above the industry average of 6.80%.
The last Return On Invested Capital (18.77%) for DOCS is above the 3 year average (14.17%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.52% | ||
| ROE | 22.93% | ||
| ROIC | 18.77% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
1.3 Margins
With an excellent Profit Margin value of 39.88%, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Profit Margin of DOCS has grown nicely.
DOCS has a Operating Margin of 40.46%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
DOCS's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 90.14%, DOCS belongs to the best of the industry, outperforming 97.14% of the companies in the same industry.
In the last couple of years the Gross Margin of DOCS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.46% | ||
| PM (TTM) | 39.88% | ||
| GM | 90.14% |
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), DOCS is creating some value.
The number of shares outstanding for DOCS has been increased compared to 1 year ago.
The number of shares outstanding for DOCS has been increased compared to 5 years ago.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 44.91 indicates that DOCS is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 44.91, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 44.91 |
ROIC/WACC1.8
WACC10.43%
2.3 Liquidity
A Current Ratio of 6.47 indicates that DOCS has no problem at all paying its short term obligations.
DOCS's Current ratio of 6.47 is amongst the best of the industry. DOCS outperforms 94.29% of its industry peers.
A Quick Ratio of 6.47 indicates that DOCS has no problem at all paying its short term obligations.
DOCS has a Quick ratio of 6.47. This is amongst the best in the industry. DOCS outperforms 94.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.47 | ||
| Quick Ratio | 6.47 |
3. Growth
3.1 Past
DOCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.27%, which is quite impressive.
DOCS shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 79.21% yearly.
Looking at the last year, DOCS shows a quite strong growth in Revenue. The Revenue has grown by 19.45% in the last year.
The Revenue has been growing by 37.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)43.27%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%28.57%
Revenue 1Y (TTM)19.45%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%15.19%
3.2 Future
DOCS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.47% yearly.
DOCS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.87% yearly.
EPS Next Y9.5%
EPS Next 2Y9.77%
EPS Next 3Y11.27%
EPS Next 5Y13.47%
Revenue Next Year11.99%
Revenue Next 2Y11.46%
Revenue Next 3Y11.53%
Revenue Next 5Y11.87%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 45.67, DOCS can be considered very expensive at the moment.
Based on the Price/Earnings ratio, DOCS is valued a bit cheaper than the industry average as 71.43% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.53. DOCS is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 40.06, which means the current valuation is very expensive for DOCS.
The rest of the industry has a similar Price/Forward Earnings ratio as DOCS.
When comparing the Price/Forward Earnings ratio of DOCS to the average of the S&P500 Index (23.04), we can say DOCS is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 45.67 | ||
| Fwd PE | 40.06 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as DOCS.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 62.86% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 44.36 | ||
| EV/EBITDA | 44.9 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of DOCS may justify a higher PE ratio.
PEG (NY)4.81
PEG (5Y)0.58
EPS Next 2Y9.77%
EPS Next 3Y11.27%
5. Dividend
5.1 Amount
No dividends for DOCS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
68.05
+1.02 (+1.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners90.54%
Inst Owner Change1.17%
Ins Owners1.94%
Ins Owner Change0.09%
Market Cap12.75B
Analysts76.15
Price Target70.95 (4.26%)
Short Float %3.62%
Short Ratio3.14
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.11%
Min EPS beat(2)17.55%
Max EPS beat(2)36.67%
EPS beat(4)4
Avg EPS beat(4)25.17%
Min EPS beat(4)15.86%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)24.03%
EPS beat(12)12
Avg EPS beat(12)21.73%
EPS beat(16)16
Avg EPS beat(16)33.54%
Revenue beat(2)2
Avg Revenue beat(2)1.95%
Min Revenue beat(2)1.38%
Max Revenue beat(2)2.52%
Revenue beat(4)4
Avg Revenue beat(4)4.39%
Min Revenue beat(4)1.38%
Max Revenue beat(4)8.16%
Revenue beat(8)7
Avg Revenue beat(8)3.34%
Revenue beat(12)9
Avg Revenue beat(12)2.13%
Revenue beat(16)12
Avg Revenue beat(16)2.76%
PT rev (1m)1.79%
PT rev (3m)13.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.84%
EPS NY rev (1m)-0.38%
EPS NY rev (3m)6.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.3%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)1.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 45.67 | ||
| Fwd PE | 40.06 | ||
| P/S | 21.62 | ||
| P/FCF | 44.36 | ||
| P/OCF | 43.33 | ||
| P/B | 12.43 | ||
| P/tB | 13.62 | ||
| EV/EBITDA | 44.9 |
EPS(TTM)1.49
EY2.19%
EPS(NY)1.7
Fwd EY2.5%
FCF(TTM)1.53
FCFY2.25%
OCF(TTM)1.57
OCFY2.31%
SpS3.15
BVpS5.48
TBVpS5
PEG (NY)4.81
PEG (5Y)0.58
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.52% | ||
| ROE | 22.93% | ||
| ROCE | 22.84% | ||
| ROIC | 18.77% | ||
| ROICexc | 96.31% | ||
| ROICexgc | 172.66% | ||
| OM | 40.46% | ||
| PM (TTM) | 39.88% | ||
| GM | 90.14% | ||
| FCFM | 48.73% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexcg growth 3Y3.35%
ROICexcg growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score8
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 62.32% | ||
| Cap/Sales | 1.15% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 117.9% | ||
| Profit Quality | 122.2% | ||
| Current Ratio | 6.47 | ||
| Quick Ratio | 6.47 | ||
| Altman-Z | 44.91 |
F-Score8
WACC10.43%
ROIC/WACC1.8
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)43.27%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%28.57%
EPS Next Y9.5%
EPS Next 2Y9.77%
EPS Next 3Y11.27%
EPS Next 5Y13.47%
Revenue 1Y (TTM)19.45%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%15.19%
Revenue Next Year11.99%
Revenue Next 2Y11.46%
Revenue Next 3Y11.53%
Revenue Next 5Y11.87%
EBIT growth 1Y26.79%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year15.19%
EBIT Next 3Y13.36%
EBIT Next 5Y12.98%
FCF growth 1Y54.23%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y53.19%
OCF growth 3Y29.24%
OCF growth 5Y59.83%